Biotech Stock Performance Review — Cellect Biotechnology … – PR Newswire (press release)

Cellect Biotechnology

Kfar Saba, Israel-based Cellect Biotechnology Ltd's stock finished Monday's session 2.84% lower at $8.56 with a total trading volume of 27,234 shares. Over the previous three months and since the start of this year, the Company's shares have advanced 34.80% and 177.02%, respectively. The stock is trading above its 200-day moving average by 53.25%. Moreover, shares of Cellect Biotech, which focuses on developing solutions for immune system regeneration in Israel, have a Relative Strength Index (RSI) of 34.93.

On May 23rd, 2017, Cellect Biotech announced that David Braun, Head of Merck Group's Medical Device Business, is joining the Company's Scientific and Medical Advisory Board. Mr. Braun has held multiple additional senior-level executive positions at leading biotech and high-tech companies, ranging from global Fortune 500 corporations to growth-oriented organizations, including Biosafe S.A., a stem cell separation leader recently acquired by GE, Newell Brands, Logitech, Chiaro Networks, and Elbit Systems. Your complete research report on APOP can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=APOP

BioDelivery Sciences

Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. declined 4.26%, ending yesterday's session at $2.25 with a total trading volume of 405,472 shares. The stock has gained 25.00% in the past month, 9.76% in the previous three months, and 28.57% on an YTD basis. The Company's shares are trading 17.71% above their 50-day moving average and 8.95% above their 200-day moving average. Moreover, shares of BioDelivery Sciences, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 56.49.

On May 26th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $4 per share.

On June 01st, 2017, BioDelivery Sciences announced that Dr. Mark A. Sirgo, President and CEO, will present at the Jefferies 2017 Healthcare Conferenceon June 06th, 2017, at9:30 a.m. ET at the Grand Hyatt in New York City. Dr. Sirgo will focus on progress with commercialization efforts and strategic initiatives supporting BELBUCA(buprenorphine) buccal film (CIII), as well as provide an update on BUNAVAIL(buprenorphine and naloxone) CIII.A free report on BDSI is just a click away at: http://dailystocktracker.com/registration/?symbol=BDSI

BioLine Rx

On Monday, Jerusalem, Israel headquartered BioLine Rx Ltd's stock saw a decline of 2.51%, to close the day at $0.82. A total volume of 177,369 shares was traded. The Company's shares are trading 8.55% below their 50-day moving average. Additionally, shares of BioLine Rx, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 41.26.

On May 18th, 2017, research firm Maxim Group upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $1 a share to $3 a share.

On June 01st, 2017, BioLine Rx announced that Genentech, a member of the Roche Group, has filed a total of three, regulatory submissions required to commence Phase-1b trials for BL-8040 in combination with atezolizumab (Tecentriq), Genentech's anti-PDL1 cancer immunotherapy, for the treatment of patients with solid tumors. The trials for pancreatic, gastric, and non-small cell cancer are expected to commence during Q2 2017 after receipt of regulatory approval. Sign up for your complimentary research report on BLRX at: http://dailystocktracker.com/registration/?symbol=BLRX

Benitec Biopharma

Shares in North Sydney, Australia headquartered Benitec Biopharma Ltd ended the day 4.02% lower at $2.39. A total volume of 50,220 shares was traded. The stock has gained 56.21% since the start of this year. The Company's shares are trading above their 200-day moving average by 16.27%. Furthermore, shares of Benitec Biopharma, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia, the UK, and the US, have an RSI of 43.99. Register for free on DailyStockTracker.com and download the latest research report on BNTC at: http://dailystocktracker.com/registration/?symbol=BNTC

--

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: contact@dailystocktracker.com Phone number: (207)-331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Read more here:
Biotech Stock Performance Review -- Cellect Biotechnology ... - PR Newswire (press release)